Relmada Therapeutics, Inc. (RLMD)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
| Previous Close | 3.8000 |
| Open | 3.8000 |
| Bid | 3.5100 x 200 |
| Ask | 3.5600 x 100 |
| Day's Range | 3.5300 - 3.8800 |
| 52 Week Range | 2.3600 - 7.2230 |
| Volume | |
| Avg. Volume | 171,333 |
| Market Cap | 114.662M |
| Beta (5Y Monthly) | 0.27 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.2800 |
| Earnings Date | Aug 06, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.88 |
- Thomson Reuters StreetEvents
Q1 2024 Relmada Therapeutics Inc Earnings Call
Q1 2024 Relmada Therapeutics Inc Earnings Call
- GuruFocus.com
Relmada Therapeutics Inc (RLMD) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
Explore key financial outcomes and strategic updates from Relmada Therapeutics' first quarter of 2024, emphasizing advancements in clinical trials and operational efficiencies.
PR NewswireRelmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the first quarter ended March 31, 2024. The Company will host a conference call today, Wednesday, May 8, at 4:30 PM Eastern Time/1:30 PM Pacific Time.
© 2024 Yahoo. All rights reserved.